The COVID-19 outbreak brought unprecedented changes to the way we live and work, especially in the R&D field. DIA Asia 2021 will be the first transnational post-COVID conference connecting industry experts and regulators to discuss key learnings and takeaways in the clinical trial and regulatory space across the Asia region. Current learnings will create a post-pandemic view on the new regulatory landscape, innovative virtual trials, Real-World Evidence and the potential implications to accelerate drug development.

Join this multi-stakeholder, neutral forum to:

• Explore new technology adoptions in revolutionizing healthcare for better diagnostics and patient outcomes.
• Receive updates on regulatory processes, policies, innovative drug review pathways, software regulations and adoption of virtual inspections.
• Learn how clinical trials are taking a more patient centric approach and get updated on the implementation of remote monitoring in Asia and the challenges that arise.
• Understand the regulations surrounding nutraceuticals/nutrition and their role in today’s healthcare.

Why you should attend:

• This is the very first time that DIA is hosting a transnational conference in the Asia region.
• The meeting provides a unique forum to gain a holistic view on the clinical trial and regulatory space post-COVID evolution.
• Join this virtual meeting from all over the world to learn about the latest developments in the Asia region.

This meeting is the ideal place for:

• Industry professionals in Pharmaceuticals and Medical Technologies involved in Research & Development, Regulatory Affairs, and Medical Affairs.
• Regulators and personnel from Health Authorities and Ministries.
• Patient and Patient Support Groups.
• Experts from Academia and Research